Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases

Jonathan Mitchell,Niedzica Camacho,Patrick Shea,Konrad Stopsack,Vijai Joseph,Oliver Simon Burren,Ryan Dhindsa,Abhishek Nag,Jacob Berchuck,Amanda O'Neill,Ali Abbasi,Anthony Zoghbi,Jesus Alegre-Diaz,Pablo Kuri-Morales,Jaime Berumen,Roberto Tapia-Conyer,Jonathan Emberson,Jason Torres,Rory Collins,Quanli Wang,David Goldstein,Athena Matakidou,Carolina Haefliger,Lauren Anderson-Dring,Ruth March,Vaidehi Jobanputra,Brian Dougherty,Keren Carss,Slave Petrovski,Philip Kantoff,Kenneth Offit,Lorelei Mucci,Mark Pomerantz,Margarete Fabre

DOI: https://doi.org/10.1101/2024.05.10.24307164

2024-05-10

Abstract:The etiology of prostate cancer, the second most common cancer in men globally, has a strong heritable component. While rare coding germline variants in several genes have been identified as risk factors from candidate gene and linkage studies, the exome-wide spectrum of causal rare variants remains to be fully explored. To more comprehensively address their contribution, we analysed data from 37,184 prostate cancer cases and 331,329 male controls from five cohorts with germline exome/genome sequencing and one cohort with imputed array data from a population enriched in low-frequency deleterious variants. Our gene-level collapsing analysis revealed that rare damaging variants in SAMHD1 as well as genes in the DNA damage response pathway (BRCA2, ATM and CHEK2) are associated with the risk of overall prostate cancer. We also found that rare damaging variants in AOX1 and BRCA2 were associated with increased severity of prostate cancer in a case-only analysis of aggressive versus non-aggressive prostate cancer. At the single variant level, we found rare non-synonymous variants in three genes (HOXB13, CHEK2, BIK) significantly associated with increased risk of overall prostate cancer and in four genes (ANO7, SPDL1, AR, TERT) with decreased risk. Altogether, this study provides deeper insights into the genetic architecture and biological basis of prostate cancer risk and severity.

What problem does this paper attempt to address?

This paper discusses the contribution of rare coding genetic variants to the risk and severity of prostate cancer. The study is based on data from 37,184 prostate cancer cases and 331,329 male controls, and uses whole-exome sequencing and genomic data analysis to gain a comprehensive understanding of the role of rare variants in the pathogenesis of prostate cancer.

The study found that rare deleterious variants in the SAMHD1 gene, as well as in the DNA damage response pathway genes BRCA2, ATM, and CHEK2, are associated with the overall risk of prostate cancer. In addition, rare deleterious variants in the AOX1 and BRCA2 genes are associated with increased severity of prostate cancer. At the individual variant level, rare missense variants in the HOXB13, CHEK2, and BIK genes are associated with an increased risk of prostate cancer, while rare variants in the ANO7, SPDL1, AR, and TERT genes are associated with a decreased risk.

This study deepens our understanding of the genetic architecture and biological basis of prostate cancer, revealing the role of rare coding genetic variants in the occurrence and development of the disease. These findings may have potential clinical significance for the prevention, screening, and treatment strategies of prostate cancer.